- AU$16.68m
- -AU$2.59m
- AU$0.00m
- 46
- 26
- 70
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.84 | ||
| Price to Tang. Book | 0.84 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 36.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.41% | ||
| Return on Equity | -15.47% | ||
| Operating Margin | -796.63% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | n/a | 0 | 3.6 | 8.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 17th, 2012
- Public Since
- November 18th, 2021
- No. of Shareholders
- 78
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 69,492,501
- Address
- Level 10, 255 Pitt St, SYDNEY, 2000
- Web
- https://tissuerepair.com.au/
- Phone
- Auditors
- Pitcher Partners
Upcoming Events for TRP
Similar to TRP
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Tissue Repair share price?
As of Today at 19:21 UTC, shares in Tissue Repair are trading at AU$0.24. This share price information is delayed by 15 minutes.
How has the Tissue Repair share price performed this year?
Shares in Tissue Repair last closed at AU$0.24 and the price had moved by +14.29% over the past 365 days. In terms of relative price strength the Tissue Repair share price has outperformed the ASX All Ordinaries Index by +9.32% over the past year.
What are the analyst and broker recommendations for Tissue Repair?
The overall consensus recommendation for Tissue Repair is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Tissue Repair dividend yield?
Tissue Repair does not currently pay a dividend.
Does Tissue Repair pay a dividend?
Tissue Repair does not currently pay a dividend.
When does Tissue Repair next pay dividends?
Tissue Repair does not currently pay a dividend.
How do I buy Tissue Repair shares?
To buy shares in Tissue Repair you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tissue Repair?
As of the previous close price of AU$0.24, shares in Tissue Repair had a market capitalisation of AU$16.68m.
Where are Tissue Repair shares listed?
Here are the trading details for Tissue Repair:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: TRP
What kind of share is Tissue Repair?
Based on an overall assessment of its quality, value and momentum Tissue Repair is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tissue Repair share price forecast for 2024?
The analyst consensus target price for shares in Tissue Repair is AU$0.79. That is 229.17% above the last closing price of AU$0.24.
Analysts covering Tissue Repair currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.11 for the next financial year.
What is the trend in the Tissue Repair share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tissue Repair. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -20.89%.
As of the last closing price of AU$0.24, shares in Tissue Repair were trading -5.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tissue Repair PE Ratio?
The Tissue Repair PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tissue Repair?
We do not have data on Tissue Repair's directors